LUCID DIAGNOSTICS INC (NASDAQ:LUCD) Reports Q2 2025 Earnings In Line with Estimates, Narrower Loss Than Expected

LUCID DIAGNOSTICS INC (NASDAQ:LUCD) reported its second-quarter 2025 financial results, with revenue and earnings per share (EPS) closely aligning with analyst expectations. The company processed 2,756 EsoGuard® tests, generating $1.16 million in revenue, slightly below the consensus estimate of $1.165 million. The reported EPS of -$0.10 outperformed the anticipated -$0.1234, reflecting a narrower loss than projected.

Key Financial Highlights vs. Estimates

• Revenue: $1.16M actual vs. $1.165M estimated (nearly in line).
• EPS: -$0.10 actual vs. -$0.1234 estimated (better than expected).
• Cash Position: The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones.

Market Reaction

The stock showed modest pre-market gains of approximately 2.26%, suggesting cautious optimism following the earnings release. However, the stock has struggled over the past month, declining by nearly 14.7%, reflecting broader investor skepticism or sector-wide pressures. The slight beat on EPS may have provided some relief, but the lack of a significant revenue surprise likely tempered enthusiasm.

Press Release Takeaways

• EsoGuard Test Volume: 2,756 tests processed in Q2, reinforcing commercial progress.
• Cash Runway: The $30M+ cash position provides stability as the company navigates reimbursement and commercialization efforts.
• Strategic Focus: Continued emphasis on esophageal cancer prevention through its EsoGuard and EsoCheck technologies.

Forward-Looking Estimates

Analysts expect Q3 2025 revenue of $1.805M and an EPS of -$0.1232. For the full year, sales are projected at $6.506M with an estimated EPS of -$0.7808. The company did not provide explicit guidance in the press release, leaving investors to rely on these consensus figures.

For a deeper dive into Lucid Diagnostics’ earnings and future estimates, visit the earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.